“…In conclusion, due to heterogeneity of the data, high risk of bias, and small sample sizes, no recommendation for the use of CDV in the treatment of BKPyV-HC in adult allogeneic stem cell transplantation can be made at the moment-for intravenous use as well as intravesical treatment. Additionally, we want to emphasize the nephrotoxicity of intravenous CDV with 9.3% renal failure in this group of patients and even more kinds of renal impairment have been described; only Chu et al reported no renal impairment/toxicity for intravenous CDV 24. Interestingly, no renal toxicity was reported in intravesical CDV.…”